A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode

International Clinical Psychopharmacology

Volumn 27, Issue 1, 2012, Pages 17-26

  Martinez, James Michael ^a,i   Katon, Wayne ^e   Greist, John H ^f   Kroenke, Kurt ^b,c,d   Thase, Michael E ^g,h   Meyers, Adam L ^a   Edwards, Sara Elizabeth ^a   Marangell, Lauren B ^a   Shoemaker, Scarlett ^a   Swindle, Ralph ^a  

^a Lilly USA LLC   (United States)

^b INDIANA UNIVERSITY   (United States)

^c VA HSR and D Center for Implementing Evidence Based Practice   (United States)

^d REGENSTRIEF INSTITUTE   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f Healthcare Technology System   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

ⁱ ELI LILLY AND COMPANY   (United States)

Author keywords

duloxetine; efficacy; major depressive disorder; selective serotonin reuptake inhibitors; serotonin and norepinephrine reuptake inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; DULOXETINE; FLUOXETINE; GENERIC DRUG; HYPNOTIC AGENT; IBUPROFEN; LISINOPRIL; LORATADINE; MULTIVITAMIN; NAPROXEN; OMEPRAZOLE; PARACETAMOL; PAROXETINE; SALBUTAMOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; AGED; ARTICLE; BRIEF PAIN INVENTORY; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CERVICAL SPINE FRACTURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; CONSTIPATION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISABILITY; DISEASE SEVERITY; DIZZINESS; DRUG CHOICE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; FATIGUE; FEMALE; HAMILTON SCALE; HISPANIC; HUMAN; HYPERTENSION; HYPONATREMIA; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; NEGRO; NEPHROLITHIASIS; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE RATE; QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY SELF REPORT SCALE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; SCREENING TEST; SELF REPORT; SHEEHAN DISABILITY SCALE; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; SYSTOLIC BLOOD PRESSURE; TEMPORAL LOBE EPILEPSY; TIBIA FRACTURE; TREATMENT DURATION; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DISABILITY EVALUATION; DRUGS, GENERIC; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 83055180710     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32834ce11b     Document Type: Article

References (35)

1. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders. 4th ed, text revision Washington, DC: American Psychiatric Association.
2. Anderson IM (1998). SSRIs versus tricyclic antidepressants in depressed inpatients: A meta-analysis of efficacy and tolerability. Depress Anxiety 7 (Suppl 1):11-17.
3. Anderson IM (2000). Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability. J Affect Disord 58:19-36. (Pubitemid 30173208)
4. Barbui C, Guaiana G, Hotopf M (2004). Amitriptyline for inpatients and SSRIs for outpatients with depression? Systematic review and meta-regression analysis. Pharmacopsychiatry 37:93-97. (Pubitemid 38680328)
5. Bech P, Gram LF, Dein E, Jacobsen O, Vitger J, Bolwig TG (1975). Quantitative rating of depressive states. Acta Psychiatr Scand 51:161-170.
6. Birnbaum HG, Kessler RC, Kelley D, Ben-Hamadi R, Joish VN, Greenberg PE (2010). Employer burden of mild, moderate, and severe major depressive disorder: Mental health services utilization and costs, and work performance. Depress Anxiety 27:78-89.
7. Cleary M, Guy W (1977). Factor analysis of the Hamilton Depression Scale. Drugs Exp Clin Res 1:115-120.
8. Cleeland CS, Ryan KM (1994). Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore 23:129-138.
9. Corey-Lisle PK, Nash R, Stang P, Swindle R (2004). Response, partial response, and nonresponse in primary care treatment of depression. Arch Intern Med 164:1197-1204. (Pubitemid 39030356)
10. Dunlop BW, Li T, Kornstein SG, Friedman ES, Rothschild AJ, Pedersen R, et al. (2010). Correlation between patient and clinician assessments of depression severity in the PREVENT study. Psychiatr Res 177:177-183.
11. Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVaughn-Geiss A, Krebs EE, et al. (2008). Comparative benefits and harms of second-generation antidepressants: Background paper for the America College of Physicians. Ann Intern Med 149:734-750.
12. Gartlehner G, Thaler K, Hansen RA, Gaynes BN (2009). The general and comparative efficacy and safety of duloxetine in major depressive disorder: A systematic review and meta-analysis. Drug Saf 32:1159-1173.
13. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
14. Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS (2005). Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 143:415-426. (Pubitemid 41341413)
15. Hasin DS, Goodwin RD, Stinson FS, Grant BF (2005). Epidemiology of major depressive disorder: Results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 62:1097-1106. (Pubitemid 41396935)
16. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. (2003). The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA 289:3095-3105. (Pubitemid 37432885)
17. Khan A, Schwartz K, Kolts RL, Ridgway D, Lineberry C (2007). Relationship between depression severity entry criteria and antidepressant clinical trial outcomes. Biol Psychiatry 62:65-71. (Pubitemid 46898225)
18. Kroenke K, Spitzer RL, Williams JB (2001). The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med 16:606-613. (Pubitemid 32823891)
19. Maier W, Philipp M (1985). Improving the assessment of severity of depressive states: A reduction of the Hamilton depression scale. Pharmacopsychiatry 18:114-115. (Pubitemid 15137667)
20. Mallinckrodt CH, Prakash A, Houston JP, Swindle R, Detke MJ, Fava M (2007). Differential antidepressant symptom efficacy: Placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). Neuropsychobiology 56:73-85. (Pubitemid 351340017)
21. Nelson JC, Mazure CM, Jatlow PI, Bowers MB Jr, Price LH (2004). Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: A double-blind, randomized study. Biol Psychiatry 55:296-300. (Pubitemid 38117167)
22. Nierenberg AA (1994). The treatment of severe depression: Is there an efficacy gap between SSRI and TCA antidepressant generations? J Clin Psychiatry 55 (Supp A):55-59.
23. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC (2007). Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 62:1217-1227. (Pubitemid 350060895)
24. Rush AJ, Giles DE, Schlesser MA, Fulton CL, Weissenberger J, Burns C (1986). The Inventory for Depressive Symptomatology (IDS): Preliminary findings. Psychiatry Res 18:65-87. (Pubitemid 16085767)
25. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH (1996). The Inventory of Depressive Symptomatology (IDS): Psychometric properties. Psychol Med 26:477-486. (Pubitemid 26142491)
26. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. (2003). The 16-item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDSC), and Self-Report (QIDS-SR): A psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54:573-583. (Pubitemid 37289444)
27. Rush AJ, Bernstein IH, Trivedi MH, Carmody TJ, Wisniewski S, Mundt JC, et al. (2006). An evaluation of the quick inventory of depressive symptomatology and the Hamilton Rating Scale for depression: A sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry 59:493-501. (Pubitemid 43320536)
28. Rush JA, Carmody TJ, Reimitz PE (2000). The Inventory of Depressive Symtpomatology(IDS): Clinician (IDS-C) and Self-Report (IDS-SR) ratings of depressive symptoms. Int J Methods Psychiatr Res 9:45-59.
29. Schatzberg AF (1996-1997). Treatment of severe depression with selective serotonin reuptake inhibitors. Depress Anxiety 4:182-189.
30. Schmitt AB, Bauer M, Volz HP, Moeller H-J, Jian Q, Ninan PT, et al. (2009). Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity. Eur Arch Psychiatry Clin Neurosci 259:329-339.
31. Sheehan DV, Harnett-Sheehan K, Raj BA (1996). The measurement of disability. Int Clin Psychopharmacol 11 (Suppl 3):89-95. (Pubitemid 26373761)
32. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I (2002). Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis. Br J Psychiatry 180:396-404. (Pubitemid 34499333)
33. Spitzer RL, Kroenke K, Williams JB (1999). Validation and utility of a self-report version of PRIME-MD: The PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 282:1737-1744. (Pubitemid 29533604)
34. Thase ME, Entsuah AR, Rudolf RL (2001). Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:234-241. (Pubitemid 32183606)
35. Thase ME, Pritchett YL, Ossanna MJ, Swindle RW, Xu J, Detke MJ (2007). Efficacy of duloxetine and selective serotonin reuptake inhibitors: Comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 27:672-676. (Pubitemid 351339455)